Edity Therapeutics

Edity Therapeutics Overview

Edity is developing an exciting new platform that harnesses the immune system to deliver therapeutic proteins direct to the cytoplasm of target cells to reprogram cells and tissue back to health. The technology creates the opportunity to change the course of disease at the intracellular level via multiple mechanisms including protein replacement, target modulation, genetic correction and protein gain of function. Currently, the company is working across a number of indications, including oncology and genetic disease, while developing programs for regeneration and longevity.

Cumulative Funding Raised Over Time ($)

Latest News

Jan 16, 2024 · www.webwire.com

growth-positive

Edity Therapeutics enters into a Strategic Collaboration with Dr. Reddy's Laboratories to Advance Novel Cell Therapy Approach Using Edity's Proprietary Delivery Platform

Edity Therapeutics has announced a strategic collaboration with Dr. Reddys Laboratories Ltd. to create novel cell therapy medicines using Editys proprietary delivery platform. As part of the agreement, Dr. Reddys will provide CDMO services to support Editys clinical development and cell therapy manufacturing activities. This follows Dr. Reddys previous acquisition of an equity stake in Edity. The collaboration aims to address the challenges of cell therapies in solid tumors, including antigen heterogeneity, the immunosuppressive tumor microenvironment, and tumor resistance to death.

PartnersInvestment

Funding

Team Members

3

Employees: 11-50

Web & Social Links

Locations

Prof. Menakhem Plaut St, Rehovot, Israel

Photos & Videos

1 item(s)

Edity Therapeutics Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info